IMRALDI Biogen’s Adalimumab Biosimilar Referencing Humira, Is Launched in the European Union

Samsung Bioepis a joint venture between Samsung BioLogics and Biogen (Nasdaq: BIIB) today announced the European launch of IMRALDI, an adalimumab biosimilar referencing Humira.

As quoted in the press release:

IMRALDI is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn’s disease, paediatric Crohn’s disease, ulcerative colitis and uveitis.

The launch of IMRALDI completes Biogen’s portfolio of three anti-TNF biosimilars in Europe, with BENEPALI^TM (etanercept), a biosimilar referencing Enbrel^®2, and FLIXABI^TM (infliximab), a biosimilar referencing Remicade^®3, reinforcing the company’s commitment across therapeutic areas in rheumatology, gastroenterology and dermatology.

“We are proud to be pioneering innovation in biosimilars to help transform the lives of people in Europe with chronic autoimmune conditions,” said Ian Henshaw, Global Head of Biosimilars at Biogen. “With the addition of IMRALDI to our anti-TNF biosimilar offering, we are increasing physician choice and patient access in Europe to affordable treatments across disease areas.”

Anti-TNF therapies represent some of the EU’s largest drug expenditures, costing an estimated €7.69 billion each year from 2011 to 2014.^4,5 €10.6 billion could potentially be saved by 2020 through the availability of Biogen’s three anti-TNF biosimilars in Europe.

Click here to read the full press release.